- Citations, last 5 years
- 12
- Works, last 5 years
- 8
- h-index
- 68
- Scientists listed
- 0
- Grants since 2016
- 20
Grants received
2023–2025 · research · R43
Novel TLR-4 Agonists as Vaccine Adjuvants
Alan Thomas Johnson · Hawaii Biotech (United States) · funded by National Institutes of Health
2023–2025 · research · R43
Novel TLR-4 Agonists as Vaccine Adjuvants
Alan Thomas Johnson · Hawaii Biotech (United States) · funded by National Institutes of Health
2023–2026 · research · R43
Development of a Cross-Protective New World Encephalitic Alphavirus Subunit Vaccine
David E Clements · Hawaii Biotech (United States) · funded by National Institutes of Health
2023–2025 · research · R43
Development of a Cross-Protective New World Encephalitic Alphavirus Subunit Vaccine
David E Clements · Hawaii Biotech (United States) · funded by National Institutes of Health
2022–2025 · contract · N44
Recombinant West Nile Virus Vaccine Adjuvanted with SLA-LSQ Optimize Formulation of VSA Adjuvant
David Clements · Hawaii Biotech (United States) · funded by National Institutes of Health
2020 · research · R44
Hawaii Biotech COVID-19 Response to PA-18-591
David E Clements · Hawaii Biotech (United States) · funded by National Institutes of Health
2018–2020 · contract · N01
Development of a Therapeutic to Treat Anthrax in Humans
Alan Johnson · Hawaii Biotech (United States) · funded by National Institutes of Health
2018–2019 · contract · N01
Development of a Therapeutic to Treat Anthrax in Humans
(Contact) · Hawaii Biotech (United States) · funded by National Institutes of Health
2018–2022 · contract · N01
Development of a Therapeutic to Treat Anthrax in Humans
Alan Johnson · Hawaii Biotech (United States) · funded by National Institutes of Health
2018–2024 · contract · N01
Development of a Therapeutic to Treat Anthrax in Humans
Alan Johnson · Hawaii Biotech (United States) · funded by National Institutes of Health
2018–2023 · contract · N01
Development of a Therapeutic to Treat Anthrax in Humans
Alan Johnson · Hawaii Biotech (United States) · funded by National Institutes of Health
2016–2026 · research · R44
Chikungunya Recombinant Subunit Vaccine
David E Clements · Hawaii Biotech (United States) · funded by National Institutes of Health
2016–2023 · research · R44
Chikungunya Recombinant Subunit Vaccine
David E Clements · Hawaii Biotech (United States) · funded by National Institutes of Health
2016–2019 · research · R43
Chikungunya Recombinant Subunit Vaccine
David E Clements · Hawaii Biotech (United States) · funded by National Institutes of Health
2016–2018 · research · R43
Chikungunya Recombinant Subunit Vaccine
David E Clements · Hawaii Biotech (United States) · funded by National Institutes of Health
2016–2022 · research · R44
Chikungunya Recombinant Subunit Vaccine
David E Clements · Hawaii Biotech (United States) · funded by National Institutes of Health
2016–2025 · research · R44
Chikungunya Recombinant Subunit Vaccine
David E Clements · Hawaii Biotech (United States) · funded by National Institutes of Health
2015–2023 · research · R44
Cross-Protective Multivalent Vaccine for Tick-Borne Flaviviruses
David E Clements · Hawaii Biotech (United States) · funded by National Institutes of Health
2015–2022 · research · R44
Cross-Protective Multivalent Vaccine for Tick-Borne Flaviviruses
David E Clements · Hawaii Biotech (United States) · funded by National Institutes of Health
2015–2022 · research · R44
Cross-Protective Multivalent Vaccine for Tick-Borne Flaviviruses
David E Clements · Hawaii Biotech (United States) · funded by National Institutes of Health